NCT00055237View on ClinicalTrials.gov

Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

February 26, 2003

Primary Completion Date

March 15, 2010

Study Completion Date

March 15, 2010

Conditions
Kaposi's SarcomaHIV InfectionsHIV Seronegativity
Interventions
BIOLOGICAL

Bevacizumab

15 mg/kg day intravenously on day 1, day 8, then every 3 weeks.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00055237 - Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients | Biotech Hunter | Biotech Hunter